Provide feedbackProvide feedback

« Back

AstraZeneca's Atacand associated with lower risk of all-cause mortality in patients with HF versus losartan, data suggest

Monday, December 19 2011 | Comments
Evidence Grade 0 What's This?
Individuals with heart failure who are treated with AstraZeneca Pharmaceuticals LP's Atacand (candesartan cilexetil), an angiotensin II receptor blocker (ARB), have a lower risk of all-cause mortality than do those treated with the ARB losartan potassium, according to an analysis of data from an unselected population of patients with heart failure.

The analysis was based on data from the Swedish Heart Failure Registry and included data for 5,139 patients (mean age, 74 years) who were treated with Atacand (n=2,639) or losartan (n=2,500). The main outcome measure was all-cause mortality at one and five years.

At one year, survival for the patients who received Atacand was 90 percent, and for those who received losartan it was 83 percent. Five-year survival rates were 61 percent and 44 percent for the respective treatment groups.

Univariate analysis revealed a significant 77 percent increased risk of all-cause mortality with losartan versus Atacand, and when the investigators adjusted for propensity scores (to correct for potential selection bias) in multivariate analyses, the risk was still increased a significant 43 percent with losartan versus Atacand.

The researchers cautioned that supportive evidence for their study findings is needed before being applied to clinical practice.

"Ideally, different ARB agents should be tested against each other in randomized controlled trials," they stated.

The study was published in the Jan. 13 issue of JAMA.

AstraZeneca manufactures Atacand under a license from Takeda Pharmaceutical Co. Ltd.

Print  |  E-mail

Comments

Be the first to write a comment for this article!

You must be logged in to post a comment.